📣 VC round data is live. Check it out!
- Public Comps
- PHC Holdings
PHC Holdings Valuation Multiples
Discover revenue and EBITDA valuation multiples for PHC Holdings and similar public comparables like MedicalSystem Technology, QuidelOrtho, Anteris Technologies US, SS Innovations and more.
PHC Holdings Overview
About PHC Holdings
PHC Holdings Corp is engaged in the development, manufacture and sale of healthcare devices and services.
Founded
2013
HQ

Employees
9.8K
Website
Financials (LTM)
EV
$2B
Valuation Multiples
Start free trialPHC Holdings Financials
PHC Holdings reported last 12-month revenue of $2B and EBITDA of $331M.
In the same LTM period, PHC Holdings generated $1B in gross profit, $331M in EBITDA, and $15M in net income.
Revenue (LTM)
PHC Holdings P&L
In the most recent fiscal year, PHC Holdings reported revenue of $2B and EBITDA of $327M.
PHC Holdings is profitable as of last fiscal year, with gross margin of 46%, EBITDA margin of 14%, and net margin of 3%.
Financial data powered by Morningstar, Inc.
PHC Holdings Stock Performance
PHC Holdings has current market cap of $769M, and enterprise value of $2B.
Market Cap Evolution
PHC Holdings' stock price is $6.08.
PHC Holdings share price decreased by 2.1% in the last 30 days, and increased by 3.7% in the last year.
PHC Holdings has an EPS (earnings per share) of $0.52.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $769M | 0.1% | -2.1% | -12.3% | 3.7% | $0.52 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialPHC Holdings Valuation Multiples
PHC Holdings trades at 0.9x EV/Revenue multiple, and 6.1x EV/EBITDA.
EV / Revenue (LTM)
PHC Holdings Financial Valuation Multiples
As of May 19, 2026, PHC Holdings has market cap of $769M and EV of $2B.
PHC Holdings has a P/E ratio of 50.2x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified PHC Holdings Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


PHC Holdings Margins & Growth Rates
PHC Holdings grew revenue by 1% and EBITDA by 0% in the last fiscal year.
In the most recent fiscal year, PHC Holdings reported gross margin of 46%, EBITDA margin of 14%, and net margin of 3%.
PHC Holdings Margins
PHC Holdings Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
PHC Holdings Operational KPIs
PHC Holdings' revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
PHC Holdings' Rule of 40 is 16% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
PHC Holdings' Rule of X is 17% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
PHC Holdings Competitors
PHC Holdings competitors include MedicalSystem Technology, QuidelOrtho, Anteris Technologies US, SS Innovations, Bioventus, Advanced Medical Solutions Group, Nanosonics, Yidu Tech, HealthStream and ChemoMetec.
Most PHC Holdings public comparables operate across Healthcare Software, Medical Devices, B2B SaaS, DeepTech, HealthTech and Vertical SaaS.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 15.8x | 14.2x | 53.6x | 62.9x | |||
| 1.3x | 1.3x | 5.8x | 5.7x | |||
| 239.4x | 107.1x | (5.1x) | (4.7x) | |||
| 18.8x | — | (133.6x) | — | |||
| 1.7x | 1.6x | 8.2x | 8.1x | |||
| 2.6x | 2.5x | 12.0x | 11.5x | |||
| 4.2x | 4.0x | 26.5x | 35.4x | |||
| 3.8x | — | (30.4x) | — | |||
This data is available for Pro users. Sign up to see all PHC Holdings competitors and their valuation data. Start Free Trial | ||||||
PHC Holdings Funding History
Before going public, PHC Holdings raised $184M in total equity funding, across 1 round.
PHC Holdings Funding Rounds
PHC Holdings M&A Activity
PHC Holdings has acquired 2 companies to date.
Last acquisition by PHC Holdings was on June 15th 2023. PHC Holdings acquired Scimed Life Sciences for undisclosed valuation.
Latest Acquisitions by PHC Holdings
| Description | SciMed Life Sciences is a Singapore-headquartered distributor of laboratory instruments for clinical diagnostics, biotechnology, and agriculture. The company supplies PCR systems, centrifuges, and microscopy equipment from brands like Analytik Jena across Southeast Asia. | Ascensia Diabetes Care is a Basel-headquartered global provider of blood glucose monitoring systems and diabetes management solutions. The company offers CONTOUR NEXT meters with high-accuracy testing strips and connected apps for data tracking. Operating in over 100 countries, it serves more than 20 million users through partnerships with pharmacies and healthcare providers. Spun out from Bayer in 2016 and majority-owned by Abbott, Ascensia focuses on integrated digital platforms for self-management. |
| HQ Country | ||
| HQ City | Singapore | Basel |
| Deal Date | 15 Jun 2023 | 5 Jan 2016 |
| Valuation | undisclosed | $1B |
| EV/Revenue | ||
| EV/EBITDA | ||
This data is available for Pro users. Sign up to see all PHC Holdings acquisitions and their M&A valuation multiples. Start Free Trial | ||
PHC Holdings Investment Activity
PHC Holdings has invested in 3 companies to date.
Latest investment by PHC Holdings was on March 23rd 2023. PHC Holdings invested in Lunaphore in their $32M Series D round (EV/Revenue multiple of ).
Latest Investments by PHC Holdings
| Description | Lunaphore Technologies is a Lausanne-headquartered spatial biology company founded in 2014. The firm develops the COMET platform, an automated system using microfluidic chips for multiplex immunofluorescence and in situ hybridization assays. Solutions enable simultaneous detection of over 40 biomarkers in tissue samples at subcellular resolution for immuno-oncology and translational research. | Lunaphore Technologies is a Lausanne-headquartered spatial biology company founded in 2014. The firm develops the COMET platform, an automated system using microfluidic chips for multiplex immunofluorescence and in situ hybridization assays. Solutions enable simultaneous detection of over 40 biomarkers in tissue samples at subcellular resolution for immuno-oncology and translational research. | Aiforia Technologies PLC equips pathologists and scientists in preclinical and clinical labs with powerful deep learning artificial intelligence software for translating images into discoveries, decisions, and diagnoses. The cloud based Aiforia products and services plan to escalate the efficiency and precision of medical image analysis beyond current capabilities, across a variety of fields from oncology to neuroscience and more. | Lunaphore Technologies is a Lausanne-headquartered spatial biology company founded in 2014. The firm develops the COMET platform, an automated system using microfluidic chips for multiplex immunofluorescence and in situ hybridization assays. Solutions enable simultaneous detection of over 40 biomarkers in tissue samples at subcellular resolution for immuno-oncology and translational research. | |
| HQ Country | |||||
| HQ City | Lausanne | Lausanne | Helsinki | Lausanne | |
| Deal Date | 23 Mar 2023 | 1 Aug 2021 | 8 Jun 2021 | 6 Feb 2020 | |
| Round | Series D | Series A | Series B | Series C | |
| Raised | $32M | $12M | $15M | $24M | |
| Investors | Ernst Gohner Stiftung; OCCIDENT; PHC Holdings; redalpine; Swiss Entrepreneurs Fund | Alpana Ventures; OCCIDENT; PHC Holdings | PHC Holdings | Alpana Ventures; OCCIDENT; PHC Holdings; redalpine | |
| Valuation | undisclosed | undisclosed | undisclosed | undisclosed | |
| EV/Revenue | |||||
| EV/EBITDA | |||||
This data is available for Pro users. Sign up to see all PHC Holdings investments and their VC round multiples. Start Free Trial | |||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout PHC Holdings
| When was PHC Holdings founded? | PHC Holdings was founded in 2013. |
| Where is PHC Holdings headquartered? | PHC Holdings is headquartered in Japan. |
| How many employees does PHC Holdings have? | As of today, PHC Holdings has over 9K employees. |
| Who is the CEO of PHC Holdings? | PHC Holdings' CEO is Kyoko Deguchi. |
| Is PHC Holdings publicly listed? | Yes, PHC Holdings is a public company listed on Tokyo Stock Exchange. |
| What is the stock symbol of PHC Holdings? | PHC Holdings trades under 6523 ticker. |
| When did PHC Holdings go public? | PHC Holdings went public in 2021. |
| Who are competitors of PHC Holdings? | PHC Holdings main competitors include MedicalSystem Technology, QuidelOrtho, Anteris Technologies US, SS Innovations, Bioventus, Advanced Medical Solutions Group, Nanosonics, Yidu Tech, HealthStream, ChemoMetec. |
| What is the current market cap of PHC Holdings? | PHC Holdings' current market cap is $769M. |
| What is the current revenue of PHC Holdings? | PHC Holdings' last 12 months revenue is $2B. |
| What is the current revenue growth of PHC Holdings? | PHC Holdings revenue growth (NTM/LTM) is 1%. |
| What is the current EV/Revenue multiple of PHC Holdings? | Current revenue multiple of PHC Holdings is 0.9x. |
| Is PHC Holdings profitable? | Yes, PHC Holdings is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of PHC Holdings? | PHC Holdings' last 12 months EBITDA is $331M. |
| What is PHC Holdings' EBITDA margin? | PHC Holdings' last 12 months EBITDA margin is 14%. |
| What is the current EV/EBITDA multiple of PHC Holdings? | Current EBITDA multiple of PHC Holdings is 6.1x. |
| What is the current FCF of PHC Holdings? | PHC Holdings' last 12 months FCF is $133M. |
| What is PHC Holdings' FCF margin? | PHC Holdings' last 12 months FCF margin is 6%. |
| What is the current EV/FCF multiple of PHC Holdings? | Current FCF multiple of PHC Holdings is 15.1x. |
| How many companies PHC Holdings has acquired to date? | As of May 2026, PHC Holdings has acquired 2 companies. |
| What was the largest acquisition by PHC Holdings? | $1B acquisition of Ascensia Diabetes Care on 5th January 2016 was the largest M&A PHC Holdings has done to date. |
| What companies PHC Holdings acquired? | PHC Holdings acquired Ascensia Diabetes Care and Scimed Life Sciences. |
| In how many companies PHC Holdings has invested to date? | As of May 2026, PHC Holdings has invested in 3 companies. |
| What was the last PHC Holdings investment? | On 23rd March 2023 PHC Holdings invested in Lunaphore, participating in a $32M Series D round, alongside Ernst Gohner Stiftung, OCCIDENT, redalpine, and Swiss Entrepreneurs Fund. |
| In what companies PHC Holdings invested in? | PHC Holdings invested in Lunaphore, Aiforia, and KAKEHASHI. |
See public comps similar to PHC Holdings
Lists including PHC Holdings
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.


